SMC accepts nepafenac (Nevanac) for the reduction in the risk of postoperative macular oedema associated with cataract surgery

Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium (SMC) has accepted nepafenac (Nevanac®) for use in NHS Scotland, for the reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.   Please see link for details.

Full Story →